|
1
|
Global Burden of Disease Cancer
Collaboration. JAMA Oncol. 1:505–527. 2015.PubMed/NCBI
|
|
2
|
Schirripa M and Lenz HJ: Biomarker in CRC.
Cancer J. 22:156–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamazaki K, Nagase M, Tamagawa H, Ueda S,
Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T,
et al: Randomized phase III study of bevacizumab plus FOLFIRI and
bevacizumab plus mFOLFOX6 as first-line treatment for patients with
metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27:1539–1546.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kjersem JB, Ikdahl T, Lingjaerde OC, Guren
T, Tveit KM and Kure EH: Plasma microRNAs predicting clinical
outcome in metastatic colorectal cancer patients receiving
first-line oxaliplatin-based treatment. Mol Oncol. 8:59–67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X,
Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for
early detection of colorectal cancer. Int J Cancer. 136:152–161.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rasmussen MH, Jensen NF, Tarpgaard LS,
Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL,
Lindebjerg J, Hansen F, et al: High expression of microRNA-625-3p
is associated with poor response to first-line oxaliplatin based
treatment of metastatic colorectal cancer. Mol Oncol. 7:637–646.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li XW, Qiu SJ and Zhang X: Overexpression
of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil
induced apoptosis through regulating CXCR1. Eur Rev Med Pharmacol
Sci. 22:7240–7250. 2018.PubMed/NCBI
|
|
13
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R,
Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin
resistance in colorectal cancer cells by negatively regulating ATM
kinase. Mol Oncol. 8:83–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Q, Xia HW, Ge XJ, Zhang YC, Tang QL
and Bi F: Serum miR-19a predicts resistance to FOLFOX chemotherapy
in advanced colorectal cancer cases. Asian Pac J Cancer Prev.
14:7421–7426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W,
Xie X and Cheng X: miR-375 mediated acquired chemo-resistance in
cervical cancer by facilitating EMT. PLoS One. 9:e1092992014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishibeppu K, Komatsu S, Imamura T, Kiuchi
J, Kishimoto T, Arita T, Kosuga T, Konishi H, Kubota T, Shiozaki A,
et al: Plasma microRNA profiles: Identification of miR-1229-3p as a
novel chemoresistant and prognostic biomarker in gastric cancer.
Sci Rep. 10:31612020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Komatsu S, Ichikawa D, Kawaguchi T,
Takeshita H, Miyamae M, Ohashi T, Okajima W, Imamura T, Kiuchi J,
Arita T, et al: Plasma microRNA profiles: Identification of miR-23a
as a novel biomarker for chemoresistance in esophageal squamous
cell carcinoma. Oncotarget. 7:62034–62048. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konishi H, Ichikawa D, Komatsu S, Shiozaki
A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T,
Kawaguchi T, et al: Detection of gastric cancer-associated
microRNAs on microRNA microarray comparing pre- and post-operative
plasma. Br J Cancer. 106:740–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Komatsu S, Ichikawa D, Hirajima S,
Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H,
Shiozaki A, et al: Plasma microRNA profiles: Identification of
miR-25 as a novel diagnostic and monitoring biomarker in
oesophageal squamous cell carcinoma. Br J Cancer. 111:1614–1624.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang SY, Shiboski S, Belair CD, Cooperberg
MR, Simko JP, Stoppler H, Cowan J, Carroll PR and Blelloch R:
miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology
in prostate cancer patients eligible for active surveillance. PLoS
One. 9:e985972014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sheng S, Xie L, Wu Y, Ding M, Zhang T and
Wang X: MiR-144 inhibits growth and metastasis in colon cancer by
down-regulating SMAD4. Biosci Rep. 39:392019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu J, Ruan J, Liu X, Xiao C and Xiong J:
MicroRNA-301a-3p suppressed the progression of hepatocellular
carcinoma via targeting VGLL4. Pathol Res Pract. 214:2039–2045.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu X, Ma SP, Yang D, Liu Y, Wang YP, Lin
T, Li YX, Yang SH, Zhang WC and Wang XL: miR-142-3p suppresses cell
growth by targeting CDK4 in colorectal Cancer. Cell Physiol
Biochem. 51:1969–1981. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang M, Xu B, Li X, Shang Y, Chu Y, Wang
W, Chen D, Wu N, Hu S, Zhang S, et al: O-GlcNAcylation promotes
colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2
regulatory feedback circuit. Oncogene. 38:301–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng H, Xue J, Yang S, Chen Y, Wang Y,
Zhu Y, Wang X, Kuang D, Ruan Q, Duan Y, et al: Co-targeting of
IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular
carcinoma development. Oncotarget. 8:47984–47997. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen Y, Qi L, Li Y, Zhang Y, Gao X, Zhu Y
and Wang K: The downregulation of lncRNA PGM5-AS1 inhibits the
proliferation and metastasis via increasing miR-484 expression in
colorectal cancer. Cancer Biother Radiopharm. 36:220–229. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang L, Men WL, Yan KM, Tie J, Nie YZ and
Xiao HJ: MiR-340-5p is a potential prognostic indicator of
colorectal cancer and modulates ANXA3. Eur Rev Med Pharmacol Sci.
22:4837–4845. 2018.PubMed/NCBI
|
|
31
|
Chang W, Zhang L, Xian Y and Yu Z:
MicroRNA-33a promotes cell proliferation and inhibits apoptosis by
targeting PPARα in human hepatocellular carcinoma. Exp Ther Med.
13:2507–2514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Y, Huang Z, Wu S, Zang X, Liu M and
Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and
promotes osteosarcoma cell resistance to cisplatin by
down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SH, Kim GJ, Umemura T, Lee SG and Cho
KJ: Aberrant expression of plasma microRNA-33a in an
atherosclerosis-risk group. Mol Biol Rep. 44:79–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lefebvre P, Chinetti G, Fruchart JC and
Staels B: Sorting out the roles of PPAR α in energy metabolism and
vascular homeostasis. J Clin Invest. 116:571–580. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aoyama T, Peters JM, Iritani N, Nakajima
T, Furihata K, Hashimoto T and Gonzalez FJ: Altered constitutive
expression of fatty acid-metabolizing enzymes in mice lacking the
peroxisome proliferator-activated receptor alpha (PPARalpha). J
Biol Chem. 273:5678–5684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Panigrahy D, Kaipainen A, Huang S,
Butterfield CE, Barnés CM, Fannon M, Laforme AM, Chaponis DM,
Folkman J and Kieran MW: PPARalpha agonist fenofibrate suppresses
tumor growth through direct and indirect angiogenesis inhibition.
Proc Natl Acad Sci USA. 105:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang N, Chu ES, Zhang J, Li X, Liang Q,
Chen J, Chen M, Teoh N, Farrell G, Sung JJ, et al: Peroxisome
proliferator activated receptor alpha inhibits hepatocarcinogenesis
through mediating NF-κB signaling pathway. Oncotarget. 5:8330–8340.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grau R, Punzón C, Fresno M and Iñiguez MA:
Peroxisome-proliferator-activated receptor α agonists inhibit
cyclo-oxygenase 2 and vascular endothelial growth factor
transcriptional activation in human colorectal carcinoma cells via
inhibition of activator protein-1. Biochem J. 395:81–88. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee G, Liang C, Park G, Jang C, Jung JU
and Chung J: UVRAG is required for organ rotation by regulating
Notch endocytosis in Drosophila. Dev Biol. 356:588–597. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang
S, Chen R, McLendon RE, Friedman AH, Keir ST, et al: miR-33a
promotes glioma-initiating cell self-renewal via PKA and NOTCH
pathways. J Clin Invest. 124:4489–4502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Katoh M and Katoh M: Notch signaling in
gastrointestinal tract (Review). Int J Oncol. 30:247–251.
2007.PubMed/NCBI
|
|
42
|
Meng RD, Shelton CC, Li Y-M, Qin LX,
Notterman D, Paty PB and Schwartz GK: gamma-Secretase inhibitors
abrogate oxaliplatin-induced activation of the Notch-1 signaling
pathway in colon cancer cells resulting in enhanced
chemosensitivity. Cancer Res. 69:573–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao L, Zhang D, Ma H, Jin M, Huang F and
Zhang T: High VEGF-A level at baseline predicts poor treatment
effect of bevacizumab-based chemotherapy in metastatic colorectal
cancer: A meta-analysis. Panminerva Med. 58:48–58. 2016.PubMed/NCBI
|
|
44
|
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W,
Wang G, Wei Y, Zou X, Zhang S, et al: HES1 promotes colorectal
cancer cell resistance to 5 Fu by inducing of EMT and ABC
transporter proteins. J Cancer. 8:2802–2808. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou Y, Zang X, Huang Z and Zhang C: TWIST
interacts with endothelin-1/endothelin A receptor signaling in
osteosarcoma cell survival against cisplatin. Oncol Lett.
5:857–861. 2013. View Article : Google Scholar : PubMed/NCBI
|
